Sparsentan in Combination With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With IgA Nephropathy (IgAN): A Case Series
Poster
Published on October 25, 2024
About the research
Summary
Background
- Sparsentan is a Dual Endothelin Angiotensin Receptor Antagonist (DEARA) indicated to slow kidney function decline in adults with primary IgA nephropathy who are at risk for disease progression1-5
- Previous clinical data from PROTECT open-label extension (OLE) period indicated that adding an SGLT2i to stable sparsentan demonstrated a benefit on proteinuria reduction and was generally well tolerated6
- Real-world evidence on the use of sparsentan and SGLT2is is limited1
Aim
- The objective of this case series was to report the clinical features and treatment responses of 4 patients with IgA nephropathy receiving sparsentan in combination with an SGLT2i in a real-world setting1
Approach
- Patients were selected by their healthcare professional (HCP) for inclusion in this case series1
- Eligibility criteria included1:
- Biopsy-proven IgA nephropathy
- Sparsentan treatment for ≥3 months
- Received an SGLT2i concurrently with sparsentan
- Patient consent
- Duration of follow-up on sparsentan ranged from 3 to 10 months, with all patients receiving ongoing sparsentan and SGLT2i combination treatment at last follow-up1
- All patients received sparsentan in combination with the SGLT2i dapagliflozin1
Key findings
- Combining sparsentan and the SGLT2i, dapagliflozin1:
- Demonstrated a rapid decrease in proteinuria (urine protein-creatinine ratio [UPCR]) from sparsentan initiation to follow-up
- Led to an improvement in proteinuria regardless of estimated glomerular filtration rate (eGFR) or UPCR at sparsentan initiation
- Resulted in further decreases in proteinuria and albuminuria compared to the end of the previous treatment
- Showed stable eGFR and blood pressure
- Combining both treatments was generally well tolerated with no treatment discontinuations due to safety concerns1
Conclusions
- Overall, findings from this case series support the safety and effectiveness of sparsentan in combination with the SGLT2i dapagliflozin in patients with IgA nephropathy1
Footnotes
DEARA, Dual Endothelin Angiotensin Receptor Antagonist; eGFR, estimated glomerular filtration rate; HCP, healthcare professional; IgA, immunoglobulin A; OLE, open-label extension; SGLT2i, sodium-glucose cotransporter-2 inhibitor; UPCR, urine protein-creatinine ratio.
- Ravipati P et al. Poster presented at: American Society of Nephrology Kidney Week 2024; October 23-27, 2024; San Diego, CA. FR-PO906.
- Kohan DE et al. Clin Sci. 2024;138(11):645-662.
- Trachtman H et al. Expert Rev Clin Immunol. 2024;20(6):571-576.
- FILSPARI® (sparsentan) Prescribing Information. San Diego, CA: Travere Therapeutics, Inc.
- FILSPARI® (sparsentan) Summary of Product Characteristics. Paris, France: Vifor France.
- Preciado P et al. Poster presented at: World Congress of Nephrology (WCN) 2024; April 13-16, 2024; Buenos Aires, Argentina. WCN24-AB-752.
MA-SP-24-0135 | October 2025